Lorlatinib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 773 publications
Neuropsychiatric adverse events associated with lorlatinib in ALK-positive NSCLC.
Journal: The International journal of risk & safety in medicine
Published: April 13, 2026
Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study.
Journal: Future oncology (London, England)
Published: April 08, 2026
Clinical Manifestations of Primary CNS T-Cell Lymphoma: A Retrospective Study of Histopathologic, Molecular, and Neuroimaging Features.
Journal: Neurology
Published: March 17, 2026
Intracranial efficacy of systemic therapies for patients with ALK-positive non-small cell lung cancer in patients with brain metastases: a systematic review and meta-analysis.
Journal: Journal of chemotherapy (Florence, Italy)
Published: February 23, 2026
Sustained Response to Lorlatinib and Pemetrexed in ALK Fusion-Positive Anaplastic Thyroid Carcinoma With Multiple Distant Metastases: A Case Report.
Journal: JCO precision oncology
Published: February 19, 2026
Correction to: Clinical characteristics of the ALK fusion-positive bladder PMP and efficacy of lorlatinib: a two-case report and literature review.
Journal: The oncologist
Published: February 18, 2026
Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China.
Journal: Lung cancer management
Published: February 03, 2026
Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor.
Journal: Frontiers in oncology
Published: February 02, 2026
First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From ALK-Rearranged NSCLC: Case Report.
Journal: JTO clinical and research reports
Published: January 26, 2026
Concurrent naxitamab and lorlatinib in a patient with refractory high-risk neuroblastoma: a case report.
Journal: Frontiers in oncology
Published: January 17, 2026
Lorlatinib atypical safety profile in ALK-positive aNSCLC: tips for management from an Italian expert panel.
Journal: Future oncology (London, England)
Published: January 14, 2026
Case Report: TPR-ALK fusion-positive inflammatory myofibroblastic tumour treated with sequential ALK inhibitors.
Journal: Frontiers in oncology
Published: December 30, 2025
Last Updated: 04/28/2026